Compare · CRWD vs ORPH
CRWD vs ORPH
Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRWD is the larger of the two at $243.34B, about 1389.6x ORPH ($175.1M).
- CRWD has hit the wire 50 times in the past 4 weeks while ORPH has been quiet.
- CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
- Company
- CrowdStrike Holdings Inc.
- Orphazyme A/S
- Price
- $237.61-3.31%
- $0.86-5.49%
- Market cap
- $243.34B
- $175.1M
- 1M return
- +17.85%
- -
- 1Y return
- +89.19%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 50
- 0
- Recent ratings
- 25
- 0
CrowdStrike Holdings Inc.
CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.
Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest CRWD
- Director Watzinger Gerhard sold $28,629,001 worth of shares (120,000 units at $238.58) (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $4,849,421 worth of shares (20,000 units at $242.47), decreasing direct ownership by 0.26% to 7,736,019 units (SEC Form 4)
- SEC Form 144 filed by CrowdStrike Holdings Inc.
- CrowdStrike Named a Leader in Threat Intelligence by Independent Research Firm
- SEC Form 144 filed by CrowdStrike Holdings Inc.
- CrowdStrike Named the Only Customers’ Choice in the 2026 Gartner® Peer Insights™ ‘Voice of the Customer’ for Identity Threat Detection and Response (ITDR)
- Director Austin Roxanne S sold $11,880,000 worth of shares (50,000 units at $237.60) and converted options into 50,000 shares (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $4,408,701 worth of shares (20,000 units at $220.44), decreasing direct ownership by 0.26% to 7,756,019 units (SEC Form 4)
- SEC Form 144 filed by CrowdStrike Holdings Inc.
- PRESIDENT AND CEO Kurtz George sold $4,191,076 worth of shares (20,000 units at $209.55), decreasing direct ownership by 0.26% to 7,776,019 units (SEC Form 4)
Latest ORPH
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 20-F filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F filed by Orphazyme A/S